File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/nmo.14220
- Scopus: eid_2-s2.0-85111697508
- PMID: 34337829
- WOS: WOS:000760394800015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis
Title | Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis |
---|---|
Authors | |
Keywords | drugs dysphagia meta-analysis pharmacotherapy systematic review treatment |
Issue Date | 2022 |
Citation | Neurogastroenterology and Motility, 2022, v. 34, n. 3, article no. e14220 How to Cite? |
Abstract | Background: This systematic review and meta-analysis aimed to evaluate the effects of pharmacological agents for neurogenic oropharyngeal dysphagia based on evidence from randomized controlled trials (RCTs). Methods: Electronic databases were systematically searched between January 1970 and March 2021. Two reviewers independently extracted and synthesized the data. The outcome measure was changed in (any) relevant clinical swallowing-related characteristics. Key results: Data from 2186 dysphagic patients were collected from 14 RCT studies across a range of pharmacotherapies. The pooled effect size of transient receptor potential (TRP) channel agonists was large compared to placebo interventions (SMD[95%CI] =1.27[0.74,1.80], p < 0.001; I2 = 79%). Data were limited for other pharmacological agents and the overall pooled effect size of these agents was non-significant (SMD [95% CI] =0.25 [−0.24, 0.73]; p = 0.31; I2 = 85%). When analyzed separately, large effect sizes were observed with Nifedipine (SMD[95%CI] =1.13[0.09,2.18]; p = 0.03) and Metoclopramide (SMD[95%CI] =1.68[1.08,2.27]; p < 0.001). By contrast, the effects of angiotensin-converting enzyme (ACE) inhibitors (SMD[95%CI] = −0.67[−2.32,0.99]; p = 0.43; I2 = 61%), Physostigmine (SMD[95%CI] = −0.05[−1.03,0.93]; p = 0.92) and Glyceryl Trinitrate (GTN) (SMD [95% CI] = −0.01 [−0.11, 0.08]; p = 0.78) were non-significant. Within stroke patients, subgroup analysis showed that TRP channel agonists had a moderate pooled effect size (SMD[95%CI] =0.74[0.10,1.39]; p = 0.02; I2 = 82%) whereas the effects of other agents were non-significant (SMD[95%CI] =0.40[−0.04,0.84]; p = 0.07; I2 = 87%). Conclusions & Inferences: Our results showed that TRP channel agonists, Nifedipine and Metoclopromide may be beneficial for neurogenic dysphagic patients. Large scale, multicenter clinical trials are warranted to fully explore their therapeutic effects on swallowing. |
Persistent Identifier | http://hdl.handle.net/10722/334773 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.312 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheng, Ivy | - |
dc.contributor.author | Sasegbon, Ayodele | - |
dc.contributor.author | Hamdy, Shaheen | - |
dc.date.accessioned | 2023-10-20T06:50:38Z | - |
dc.date.available | 2023-10-20T06:50:38Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Neurogastroenterology and Motility, 2022, v. 34, n. 3, article no. e14220 | - |
dc.identifier.issn | 1350-1925 | - |
dc.identifier.uri | http://hdl.handle.net/10722/334773 | - |
dc.description.abstract | Background: This systematic review and meta-analysis aimed to evaluate the effects of pharmacological agents for neurogenic oropharyngeal dysphagia based on evidence from randomized controlled trials (RCTs). Methods: Electronic databases were systematically searched between January 1970 and March 2021. Two reviewers independently extracted and synthesized the data. The outcome measure was changed in (any) relevant clinical swallowing-related characteristics. Key results: Data from 2186 dysphagic patients were collected from 14 RCT studies across a range of pharmacotherapies. The pooled effect size of transient receptor potential (TRP) channel agonists was large compared to placebo interventions (SMD[95%CI] =1.27[0.74,1.80], p < 0.001; I2 = 79%). Data were limited for other pharmacological agents and the overall pooled effect size of these agents was non-significant (SMD [95% CI] =0.25 [−0.24, 0.73]; p = 0.31; I2 = 85%). When analyzed separately, large effect sizes were observed with Nifedipine (SMD[95%CI] =1.13[0.09,2.18]; p = 0.03) and Metoclopramide (SMD[95%CI] =1.68[1.08,2.27]; p < 0.001). By contrast, the effects of angiotensin-converting enzyme (ACE) inhibitors (SMD[95%CI] = −0.67[−2.32,0.99]; p = 0.43; I2 = 61%), Physostigmine (SMD[95%CI] = −0.05[−1.03,0.93]; p = 0.92) and Glyceryl Trinitrate (GTN) (SMD [95% CI] = −0.01 [−0.11, 0.08]; p = 0.78) were non-significant. Within stroke patients, subgroup analysis showed that TRP channel agonists had a moderate pooled effect size (SMD[95%CI] =0.74[0.10,1.39]; p = 0.02; I2 = 82%) whereas the effects of other agents were non-significant (SMD[95%CI] =0.40[−0.04,0.84]; p = 0.07; I2 = 87%). Conclusions & Inferences: Our results showed that TRP channel agonists, Nifedipine and Metoclopromide may be beneficial for neurogenic dysphagic patients. Large scale, multicenter clinical trials are warranted to fully explore their therapeutic effects on swallowing. | - |
dc.language | eng | - |
dc.relation.ispartof | Neurogastroenterology and Motility | - |
dc.subject | drugs | - |
dc.subject | dysphagia | - |
dc.subject | meta-analysis | - |
dc.subject | pharmacotherapy | - |
dc.subject | systematic review | - |
dc.subject | treatment | - |
dc.title | Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1111/nmo.14220 | - |
dc.identifier.pmid | 34337829 | - |
dc.identifier.scopus | eid_2-s2.0-85111697508 | - |
dc.identifier.volume | 34 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | article no. e14220 | - |
dc.identifier.epage | article no. e14220 | - |
dc.identifier.eissn | 1365-2982 | - |
dc.identifier.isi | WOS:000760394800015 | - |